There were several clinical reports of combination therapy targeting NF-κB for pancreatic cancer by using NF-κB inhibitors such as a curcumin [21], nafamostat mesilate [22, 23], bortezomib [24], thalidomide [25], and lenalidomide [26]. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.